Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

5.535 -0.055 (-0.98%)
Streaming Delayed Price Updated: 10:23 AM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verastem, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
News headline image
Why KalVista Pharmaceuticals Shares Are Trading Lower By 59%; Here Are 89 Biggest Movers From Yesterday ↗
   Losers 
Via Benzinga
News headline image
S&P 500 Rises 100 Points; Nasdaq Up 3% ↗
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday. 
Via Benzinga
News headline image
RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm ↗
 
Via Benzinga
News headline image
Recap: Verastem Q4 Earnings ↗
  Verastem (NASDAQ:VSTM) reported its Q4 earnings results on Monday, March 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  Wednesday saw 127 companies set new 52-week lows. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers 
Via Benzinga
News headline image
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 44 companies hit new 52-week lows. 
Via Benzinga
News headline image
Nasdaq Surges 350 Points; Crude Oil Rises Sharply ↗
U.S. stocks traded higher midway through trading, with the Nasdaq Composite climbing more than 350 points on Tuesday. 
Via Benzinga
News headline image
Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
News headline image
7 Cheap Biotech Stocks to Buy Now ↗
These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains. 
Via InvestorPlace
News headline image
Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer
From Verastem Oncology
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
News headline image
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs ↗
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers 
Via Benzinga
News headline image
51 Biggest Movers From Thursday ↗
Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of... 
Via Benzinga
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Verastem Oncology's Return On Capital Employed Insights ↗
According to data from Benzinga Pro, during Q4, Verastem Oncology's (NASDAQ:VSTM) reported sales totaled $545.00 thousand. Despite a 27.67% increase in earnings, the company posted a loss of $16.48... 
Via Benzinga
News headline image
Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib Development ↗
Verastem Oncology Inc (NASDAQ: VSTM) entered into a credit facility with Oxford Finance LLC for  
Via Benzinga
News headline image
Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board
From Verastem Oncology
Via Business Wire
News headline image
87 Biggest Movers From Yesterday ↗
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares jumped 150% to close at $3.80 on Wednesday. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to... 
Via Benzinga
News headline image
Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why ↗
Truist has initiated coverage on Verastem Oncology Inc (NASDAQ: VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside. Analyst... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.